Assenagon Asset Management S.A. Clearside Biomedical, Inc. Transaction History
Assenagon Asset Management S.A.
- $54.1 Billion
- Q4 2024
A detailed history of Assenagon Asset Management S.A. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 131,913 shares of CLSD stock, worth $138,508. This represents 0.0% of its overall portfolio holdings.
Number of Shares
131,913
Previous 257,103
48.69%
Holding current value
$138,508
Previous $326,000
59.82%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CLSD
# of Institutions
50Shares Held
11.6MCall Options Held
24KPut Options Held
12.1K-
Vanguard Group Inc Valley Forge, PA2.81MShares$2.95 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.31 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.93MShares$2.03 Million0.03% of portfolio
-
Black Rock Inc. New York, NY798KShares$838,0430.0% of portfolio
-
Geode Capital Management, LLC Boston, MA764KShares$802,2600.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $63.2M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...